A diagnosis in five minutes
Thanks to the analysis of skin biomarkers, this thing promises to identify the specific needs of each user in five minutes. Developed in partnership with the Korean startup NanoEntek, Cell BioPrint is based on a technology known as lab-on-a-chip
. The analysis is done in three simple steps: an adhesive strip applied to the cheek, a buffer solution, then inserting the sample into a cartridge.
While the machine analyzes the data, a quick questionnaire and images of the skin complete the diagnosis. Result: recommendations based on your own biological characteristicsranging from the potential effectiveness of retinol to predisposition to age spots. And yeah.
A response to specific expectations
According to a study commissioned by L'Oréal, 90% of skincare users believe they waste time and money searching for the right product. This isn't really surprising when you consider that most advice is based on superficial observations or popular trends (we know you guys pick your creams on TikTok). With Cell BioPrint, L'Oréal therefore wants to offer a more reliable alternative, based on concrete scientific data.
The tool also aims to anticipate future developments in the skin. By measuring markers linked to biological aging, it promises to offer solutions to slow down this process.. Guive Balooch, director of L'Oréal's technology incubator, explains that the aim is to move from a reactive to a proactive approach, providing specific recommendations before problems manifest themselves. I would still like to ask a question, will this machine only recommend L'Oréal products? Because if that's the case, it's still very average.
A gradual deployment
This fascinating Cell BioPrint will be tested in Asia at the end of 2025, before being integrated into the group's luxury brands such as Lancôme or Yves Saint Laurent. L'Oréal is banking on this system to strengthen its positioning at the intersection of beauty, science and technology. It remains to be seen whether this innovation will be adopted on a large scale by consumers, especially since its cost and conditions of access have not yet been communicated.
